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February 21, 2006:884–92onverting enzyme inhibitors (ACEIs) and angiotensin II receptor
lockers (ARBs). The investigators present a number of highly
lausible hypotheses to explain the potential mechanisms by which
he renin-angiotensin-aldosterone system (RAAS) blockade with
hese agents might reduce the burden of AF, such as antiarrhyth-
ic effects and reversed cardiac remodeling by left ventricular
ypertrophy regression and reduced left atrial stretch.
We would like to offer additional pathophysiological insights
nto the benefits of these drugs on AF and its complications. First,
here is mounting evidence to support an association between
nflammation and AF. For example, atrial biopsies taken from
atients in AF have demonstrated evidence of inflammatory
nfiltrates within the atrial tissue (2,3). Furthermore, consistent
inks exist between inflammatory markers, such as C-reactive
rotein (CRP), tumor necrosis factor-alpha (TNF-), interleukin
IL)-6, white cell count, and the presence/development of AF. It
s also clear that angiotensin (ang) II has several proinflammatory
roperties (4). For example, ang II can act locally as a chemokine
nd inflammatory molecule, increasing the production of several
roinflammatory cytokines (e.g., IL-6 and TNF-), adhesion
olecules (such as vascular cell adhesion molecule-1 [VCAM-1]
n endothelial cells, intracellular adhesion molecule [ICAM]-1
nd osteopontin, a known macrophage chemotactic and adhesion
olecule), chemoattractant protein (MCP)-1 (further increasing
onocyte recruitment), and various selectins (such as P-selectin
nd s-selectin, leading to leukocyte tethering and rolling) (5–8).
There is also histological evidence to confirm that AF (both
ersistent and paroxysmal) can lead to increased ang II receptor
xpression (9). In a key study, Cardin et al. were able to link
ncreased atrial expression of ang II receptors with increased atrial
ell death and leukocyte infiltration, again supporting a potential
ink among the RAAS, inflammation, and AF (10). It would also
ppear that the relationship between ang II and inflammation is
eciprocal, as not only does ang II cause inflammation, but the
onverse is also true with inflammation itself acting as a stimulus
or increased ang II production.
Moreover, RAAS blockade influences the complications asso-
iated with AF; also, AF confers a hypercoagulable state, even in
he absence of underlying heart disease; abnormalities of hemo-
tasis, fibrinolysis, endothelium, and platelets have all been de-
cribed in this arrhythmia, which may increase the risk of stroke
nd thromboembolism (11). Furthermore, there is an established
ink among inflammation, AF, and thrombosis (12). Indeed, ang II
as known prothrombotic properties, and in the AF substudy of
he Losartan Intervention For End Point Reduction in Hyperten-
ion (LIFE) trial, a significant reduction occurred in stroke among
osartan- versus atenolol-treated AF patients, despite equivalent
lood pressure reduction (13).
Finally, there appears to be prevailing links between AF and
nflammation, thrombosis, and angiotensin II activation. Conse-
uently, RAAS blockade (by ACEIs and ARBs), with subsequent
eduction in AF burden and its complications, is consistent with
he reduction in the inflammatory and prothrombotic substrate
elated to AF.
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EPLY
ased on a growing body of evidence implicating inflammation in
he development of atrial fibrillation (AF) (1–3), Drs. Mascitelli,
ezzetta, Boos, and Lip have postulated that angiotensin-
onverting enzyme (ACE) inhibitors and angiotensin receptor
lockers (ARB) may prevent AF by reducing inflammation. We
gree that this is a plausible mechanism for AF prevention,
articularly because a recent randomized-controlled trial has found
hat systemic corticosteroids reduce both C-reactive protein and
he rate of recurrent AF in patients following cardioversion (2).
owever, none of the trials included in our meta-analysis (4)
ontained data on inflammatory markers; thus, we did not make
his potential mechanism a focus of our discussion. Instead, we
xamined available trial data, such as the class of medication
valuated and the patient group studied, in an attempt to explain
he significant heterogeneity in the results of individual trials (4).
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uantification of Coronary Lesions
y 64-Slice Computed Tomography
ompared With Quantitative Coronary
ngiography and Intravascular Ultrasound
ith great interest we have read the recent study by Leber et al.
1). They report an excellent accuracy of the new 64-slice com-
uted tomography to diagnose proximal coronary lesions and its
orrelation with intravascular ultrasound. This important study
eflects the rapid progression of multidetector computed tomog-
aphy (MDCT) and underscores the potential of MDCT in
linical practice. In the editorial by Achenbach and Daniel (2) it is
tated that, with these rapidly evolving techniques, MDCT will be
ble to rule out hemodynamically important stenoses in the near
uture, thereby replacing invasive diagnostic techniques. Although
e acknowledge the great improvements in MDCT to diagnose
oronary stenoses, we believe there are fundamental limitations to
his technique. In this perspective we agree with Achenbach and
aniel that there is “more than meets the (angiographic) eye”
hen it comes to coronary lesions.
Visual estimation of the degree of coronary stenoses on coronary
ngiograms remains a difficult problem in clinical practice of
nterventional cardiologists. This assessment usually results in an
verestimation of the stenosis, even when this estimation is
erformed by an experienced cardiologist (3). Although quantita-
ive coronary angiography will define the degree of stenosis more
ccurately, it still provides no information on the functional
everity of the stenosis. Fractional flow reserve was introduced to
liminate this visual bias and measure the functional significance of
lesion (4). This diagnostic procedure has since been the gold
tandard for evaluating coronary artery stenoses and has a great
alue in predicting which lesions will benefit from percutaneous
oronary interventions and which lesions will not. Therefore,
specially in case of intermediate coronary lesions, other diagnostic
ools such as myocardial perfusion imaging with methoxyisobu-
ylisonitrile (MIBI), single-photon emission computed tomogra- shy, and fractional flow reserve are needed in addition to coronary
ngiography to decide on the optimal treatment strategy in
ndividual patients.
Naturally, MDCT has some important advantages over coro-
ary angiography, as MDCT is not only able to show the luminal
arrowing, but also provides insight in surrounding tissues and
laque morphology. However, considerable doubt can be raised as
o whether stenosis visualization by MDCT will be able to
orrectly identify and differentiate between functionally significant
nd nonsignificant stenoses, in particular as quantification of
tenoses by MDCT still remains difficult (1,5). So, although
DCT may be very accurate in the detection of coronary artery
isease, when treatment strategies have to be made for individual
atients more emphasis should be given to functional instead of
natomical tests. Therefore, in our opinion, MDCT will not
eplace invasive or noninvasive procedures to evaluate the hemo-
ynamic severity of coronary lesions; rather, it will complement the
urrently available assortment of anatomy-oriented visualization
echniques.
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EPLY
e thank Dr. Wijpkema and colleagues for their interest in our
ditorial (1). They clearly outline the limitations of purely mor-
hologic imaging of coronary artery lesions. Undoubtedly, assess-
ent of the hemodynamic relevance of coronary artery stenoses—
or example, by measuring the functional flow reserve—is very
aluable for clinical decision making. This is the case, especially as
hey correctly state, “in case of intermediate coronary lesions . . . in
ddition to coronary angiography.” By no means does our editorial
uggest that we would consider computed tomography (CT)
